349 related articles for article (PubMed ID: 20466604)
1. Molecular basis for therapy resistance.
Lønning PE
Mol Oncol; 2010 Jun; 4(3):284-300. PubMed ID: 20466604
[TBL] [Abstract][Full Text] [Related]
2. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
3. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
4. What do we learn from HER2-positive breast cancer genomic profiles?
Theillet C
Breast Cancer Res; 2010; 12(3):107. PubMed ID: 20519027
[TBL] [Abstract][Full Text] [Related]
5. Gene expression predictors in breast cancer: current status, limitations and perspectives.
Desmedt C; Ruíz-García E; André F
Eur J Cancer; 2008 Dec; 44(18):2714-20. PubMed ID: 18977656
[TBL] [Abstract][Full Text] [Related]
6. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling: changing face of breast cancer classification and management.
Wesolowski R; Ramaswamy B
Gene Expr; 2011; 15(3):105-15. PubMed ID: 22268293
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.
Tan M; Yu D
Adv Exp Med Biol; 2007; 608():119-29. PubMed ID: 17993237
[No Abstract] [Full Text] [Related]
11. Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z; Shi Y; Shen Y; Cao L; Zhang W; Guan X
J Cell Mol Med; 2015 Dec; 19(12):2691-701. PubMed ID: 26305917
[TBL] [Abstract][Full Text] [Related]
12. Going beyond genetics to discover cancer targets.
Sandoval GJ; Hahn WC
Genome Biol; 2017 May; 18(1):95. PubMed ID: 28532420
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
14. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
[TBL] [Abstract][Full Text] [Related]
15. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
16. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.
Wu X; Li Y; Wang J; Wen X; Marcus MT; Daniels G; Zhang DY; Ye F; Wang LH; Du X; Adams S; Singh B; Zavadil J; Lee P; Monaco ME
PLoS One; 2013; 8(10):e77060. PubMed ID: 24155918
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer.
Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
[TBL] [Abstract][Full Text] [Related]
18. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
19. [New predictive factors for chemosensitivity of breast cancers].
Bonnefoi H; de Cremoux P
Bull Cancer; 2008 Oct; 95(10):943-50. PubMed ID: 19004724
[TBL] [Abstract][Full Text] [Related]
20. Biological considerations and clinical applications of new HER2-targeted agents.
Higa GM; Singh V; Abraham J
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
